

SAFETY DATA SHEET



GlaxoSmithKline

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material	BEECHAMS POWDERS
Synonyms	ACETYLSALICYLIC ACID AND CAFFEINE, FORMULATED PRODUCT
Company Name	GlaxoSmithKline, Corporate Environment, Health & Safety 980 Great West Road Brentford, Middlesex TW8 9GS UK
	UK General Information: +44-20-8047-5000
	Transport Emergency (EU) +44-1865-407333
	Medical Emergency +1-612-221-3999, Ext 221
	Information and Advice: US number, available 24 hours Multi-language response
	 GlaxoSmithKline, Corporate Environment, Health & Safety One Franklin Plaza, 200 N 16th Street Philadelphia, PA 19102-1225 US
	US General Information: +1-888-825-5249
	Transport Emergency (non EU) +1-703-527-3887
	US number, available 24 hours Multi-language response

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS RN	Percentage
CAFFEINE	58-08-2	6.3 to 12.2
ASPIRIN	50-78-2	48.8 to 75
NON-HAZARDOUS INGREDIENTS	Unassigned	18.7 to 39.0

3. HAZARDS IDENTIFICATION

Fire and Explosion	Assume that this product is capable of sustaining combustion.
* Health	Eye irritant. Skin irritant. Exposure might occur via eyes; skin; ingestion. Health effects information is based on hazards of components.
* Environment	Harmful to aquatic organisms.

4. FIRST-AID MEASURES

Ingestion	Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
Inhalation	Physical form suggests that risk of inhalation exposure is negligible.

Skin Contact	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.
Eye Contact	Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment	Medical treatment in cases of overexposure should be treated as an overdose of aspirin . Treat according to locally accepted protocols. For additional guidance, refer to the local poison control information centre.
Medical Conditions Caused or Aggravated by Exposure	None for occupational exposure.
Antidotes	No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards	The combustibility of the product is not known, however the packaging is combustible.
Extinguishing Media	Water or foam extinguishers are recommended. Carbon dioxide or dry powder extinguishers may be ineffective.
Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.
Hazardous Combustion Products	Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions	Wear protective clothing and equipment consistent with the degree of hazard.
Environmental Precautions	For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.
Clean-up Methods	Collect and place it in a suitable, properly labelled container for recovery or disposal.
Decontamination Procedures	No specific decontamination or detoxification procedures have been identified for this product.

7. HANDLING AND STORAGE**HANDLING**

General Requirements	No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.
-----------------------------	--

STORAGE

No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

INGREDIENT	CAFFEINE
GSK Occupational Hazard Category	2
GSK Occupational Exposure Limit	200 mcg/m3 (8 HR TWA)
INGREDIENT	ASPIRIN
GSK Occupational Hazard Category	1
GSK Occupational Exposure Limit	3000 mcg/m3 (8 HR TWA)

PERSONAL PROTECTIVE EQUIPMENT

Eye Protection	Wear approved safety glasses with side shields if eye contact is possible.
Other Equipment or Procedures	An eye wash station should be available. Wash hands and arms thoroughly after handling.

9. PHYSICAL AND CHEMICAL PROPERTIES
--

Appearance

Physical Form	Powder.
----------------------	---------

10. STABILITY AND REACTIVITY

Stability	This product is expected to be stable.
Conditions to Avoid	None for normal handling of this product.

11. TOXICOLOGICAL INFORMATION

* Oral Toxicity	Adverse effects might occur following ingestion.
* Inhalation Toxicity	Overexposure may result in irritation of the respiratory tract.
Skin Effects	Irritation might occur following direct contact.
Eye Effects	Irritation might occur following direct contact with eyes.
* Target Organ Effects	Adverse effects might occur in the following organ(s) following overexposure: impaired blood coagulation.
* Sensitisation	Unlikely to be a strong sensitiser in humans.
Genetic Toxicity	Not expected to be genotoxic under occupational exposure conditions.
Carcinogenicity	No components are listed as carcinogens by GSK, IARC, NTP or US OSHA. Not expected to produce cancer in humans under occupational exposure conditions.
* Reproductive Effects	Not expected to produce adverse effects on fertility or development under occupational exposure conditions. No adverse effects have been reported following extensive use or exposure in humans.
* Pharmacological Effects	This preparation contains ingredient(s) with the following activity: a non-steroidal anti-inflammatory substance.
Other Adverse Effects	Overexposure in the workplace might have the following effects: impaired blood coagulation; symptoms of hypersensitivity (such as skin rash, hives, itching, and/or difficulty breathing).

12. ECOLOGICAL INFORMATION

*** Summary**

This product contains an active ingredient that has been tested and which may be harmful if released directly to the environment. Appropriate precautions should be taken to limit release of this material to the environment. Local regulations and procedures should be consulted prior to environmental release.

13. DISPOSAL CONSIDERATIONS

Disposal**Recommendations**

Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.

Regulatory Requirements

Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling**Transport Information**

Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes.

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

EU Classification and Labelling

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

US OSHA Standard (29 CFR Part 1910.1200)**Classification**

Exempt when packaged for sale to consumers in a retail establishment.

Other US Regulations**TSCA Status**

Exempt

16. OTHER INFORMATION

References

GSK Hazard Determination

Date Approved/Revised 23-Aug-2006

SDS Version Number 11

SDS Sections Updated**Sections**

COMPOSITION / INFORMATION ON INGREDIENTS

ECOLOGICAL INFORMATION

Subsections

Activated Sludge Respiration

Adsorption

Algal

Algal Degradation

Bioaccumulation

Biodegradation

Crustacea

Daphnid

Distribution

Earthworm

Ecotoxicity

SDS Sections Updated**Sections**

ECOLOGICAL INFORMATION

HAZARDS IDENTIFICATION

IDENTIFICATION OF SUBSTANCE / PREPARATION AND OF
COMPANY

TOXICOLOGY INFORMATION

Subsections

EHAC Notation

Fish

GSK Environmental Hazard Category

Hydrolysis

Microbial Growth Inhibition

Microtox

Mobility

Other Adverse Effects

Other Species - Aquatic

Other Species - Terrestrial

Partitioning

Persistence/Degradation

Photolysis

Solubility

Summary

Volatility

Conditions Aggravated by Exposure

Environment

Eye Contact

Health

Ingestion

Inhalation

Overview

Skin Contact

Summary

Carcinogenicity

Eye Effects

Genetic Toxicity

Inhalation Toxicity

Oral Toxicity

Other Adverse Effects

Pharmacological Effects

Reproductive Effects

Sensitisation

Skin Toxicity

Target Organ Effects

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.